Schering Gets CNS As Second Therapeutic “Corner” Via Organon Acquisition
Executive Summary
Schering-Plough's planned acquisition of Organon would provide Schering with the entrée into the central nervous system marketplace it has been seeking
You may also be interested in...
Schering Points To 5 R&D "Stars," But Antithrombotic Shines Brightest
Schering-Plough's investigational thrombin receptor antagonist has the potential to be a transformative commercial opportunity for the drug maker. The product is one of five pipeline "stars" management highlighted during an R&D update Nov. 24, and one investors are keeping an especially close eye on
Schering Telescope Points To 5 R&D “Stars,” But TRA Shines Brightest
Schering-Plough's investigational thrombin receptor antagonist has the potential to be a transformative commercial opportunity for the drug maker. The product is one of five pipeline "stars" management highlighted during an R&D update Nov. 24, and one investors are keeping an especially close eye on
Schering Points To 5 R&D "Stars," But Antithrombotic Shines Brightest
Schering-Plough's investigational thrombin receptor antagonist has the potential to be a transformative commercial opportunity for the drug maker. The product is one of five pipeline "stars" management highlighted during an R&D update Nov. 24, and one investors are keeping an especially close eye on